Document Detail


Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.
MedLine Citation:
PMID:  19882303     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The management of patients with supra-therapeutic INR in a common clinical problem. The risk of bleeding is influenced by the intensity, variability and duration of anticoagulation, patient age, presence of co-morbidities and concomitant drug therapy. For the asymptomatic patient, warfarin discontinuation is all that is usually required but for individuals at high risk of bleeding and those with INR > 10, oral vitamin K administration is recommended. In the presence of major bleeding, treatment with intravenous vitamin K and prothrombin complex concentrate is the most effective therapy.
Authors:
Michael Makris; Joost J van Veen; Rhona Maclean
Related Documents :
6691723 - The influence of prophylactic antibiotics on the warfarin anticoagulation response in t...
9684793 - Control of oral anticoagulation in patients with the antiphospholipid syndrome--influen...
15825973 - Alcohol use and adherence to prescribed therapy among under-served latino and african-a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  29     ISSN:  1573-742X     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-29     Completed Date:  2010-04-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  171-81     Citation Subset:  IM    
Affiliation:
Sheffield Haemophilia and Thrombosis Centre, University of Sheffield, Sheffield, UK. m.makris@sheffield.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anticoagulants / administration & dosage,  adverse effects*
Blood Coagulation / drug effects*
Blood Coagulation Factors / administration & dosage
Coagulants / administration & dosage*,  adverse effects
Drug Administration Schedule
Evidence-Based Medicine
Factor VIIa / administration & dosage
Hemorrhage / blood,  chemically induced,  drug therapy*
Humans
Injections, Intravenous
Injections, Subcutaneous
International Normalized Ratio
Practice Guidelines as Topic
Recombinant Proteins / administration & dosage
Risk Assessment
Risk Factors
Treatment Outcome
Vitamin K / administration & dosage
Warfarin / administration & dosage,  adverse effects*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Blood Coagulation Factors; 0/Coagulants; 0/Recombinant Proteins; 0/recombinant FVIIa; 12001-79-5/Vitamin K; 37224-63-8/prothrombin complex concentrates; 81-81-2/Warfarin; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bifidobacterium longum HY8004 attenuates TNBS-induced colitis by inhibiting lipid peroxidation in mi...
Next Document:  Modelling Young's modulus for porous bones with microstructural variation and anisotropy.